Healthcare Services

Neoantigen Targeted Therapies Market Revenue Anticipated To Reach $21.52 Billion By 2030 With 35.5% CAGR

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Rise In Market Size Of The Neoantigen Targeted Therapies Market During The Forecast Period?

The market size for neoantigen targeted therapies has witnessed exponential growth in recent years. It is anticipated to expand from $4.71 billion in 2025 to $6.39 billion in 2026, at a compound annual growth rate (CAGR) of 35.8%. The expansion observed historically can be attributed to factors such as limited immunotherapy options, slow cancer vaccine development, early-stage genomic sequencing usage, restricted clinical trial availability, and a dependency on traditional oncology treatments.

The neoantigen targeted therapies market is anticipated to experience substantial growth over the next few years, with its size projected to reach $21.52 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 35.5%. This expansion during the forecast period is attributed to the rapid progress in personalized cancer therapies, increased investment in genomic sequencing, the broadening of clinical research collaborations, a rising adoption of combination immunotherapies, and the growing demand for precision oncology solutions. Major trends expected in this period include the increasing uptake of personalized cancer vaccines, the expansion of targeted immunotherapy research pipelines, a rise in clinical trials for neoantigen-based combination therapies, a growing need for early genetic profiling in oncology, and a surge in the development of TIL-based therapeutic approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

What Market Drivers Are Helping Shape The Neoantigen Targeted Therapies Market Expansion?

The burgeoning field of precision oncology is anticipated to fuel the expansion of the neoantigen targeted therapies market in the future. This cancer treatment methodology involves using specific genetic and molecular data from a patient’s tumor to inform the choice of targeted therapies. Within precision oncology, neoantigen-targeted therapies are employed by utilizing sophisticated genomic analysis to pinpoint distinct neoantigens present on an individual’s cancer cells. This application of neoantigen-targeted therapies within precision oncology represents a strategic approach to tackle the unique genetic profile of each patient’s tumor, thereby providing a more customized and potent treatment choice. For example, in March 2024, data from the Precision Oncology Clinical Trials & Statistics 2024 report, issued by Novotech—an Australia-based clinical contract research organization specializing in innovative therapeutics development—indicated that by November 2023, twelve treatments gained FDA approval for specific biomarker-selected indications, with six of them additionally listed in the NCCN guidelines. By the close of that year, 43% of the 217 FDA-approved oncology therapies were categorized as precision oncology, and 78 of these incorporated DNA or NGS-detectable biomarkers, underscoring the increasing importance of biomarker-guided treatments in cancer management. Consequently, the expansion of precision oncology is propelling the growth of the neoantigen targeted therapies market.

Which Segment Divisions Form The Structure Of The Neoantigen Targeted Therapies Market?

The neoantigen targeted therapies market covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospitals and Clinics, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies

What Trends Are Driving Changes In The Neoantigen Targeted Therapies Market?

Leading companies in the neglected tropical disease treatment market are focusing on creating innovative solutions, such as all-oral, field-deployable therapeutics, to simplify administration, enhance safety, and broaden access in low-resource settings. All-oral therapeutics for conditions like human African trypanosomiasis involve small-molecule drugs administered orally over a short duration, which aids in improving treatment reach, reducing the necessity for hospitalization, and lowering operational obstacles compared to conventional injectable therapies. For example, in December 2023, Sanofi S.A., a France-based multinational pharmaceutical company, unveiled Fexinidazole Winthrop, an oral treatment developed in partnership with not-for-profit organizations. Fexinidazole is a nitro-containing small molecule formulated to supersede older regimens that required intravenous delivery or hospitalization. Its oral formulation, simplified dosing schedule, and favorable safety profile make it suitable for use across both stages of certain forms of sleeping sickness, thereby expanding treatment access in remote areas. Furthermore, Fexinidazole differs significantly from traditional alternatives like melarsoprol and eflornithine, which are injectable, necessitate complex monitoring, and carry higher toxicity or operational challenges.

Which Companies Form The Competitive Landscape Of The Neoantigen Targeted Therapies Market?

Major companies operating in the neoantigen targeted therapies market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Kite Pharma Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

Access The Complete Neoantigen Targeted Therapies Market Report:

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

Which Region Commands The Largest Share Of The Neoantigen Targeted Therapies Market?

North America was the largest region in the neoantigen targeted therapies market in 2025. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neoantigen Targeted Therapies Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp

Browse Through More Reports Similar to the Global Neoantigen Targeted Therapies Market 2026, By The Business Research Company

Malaria Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/malaria-treatment-global-market-report

Infectious Disease Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/infectious-disease-therapeutics-global-market-report

Influenza Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795